SAN FRANCISCO, Nov. 18, 2024 (GLOBE NEWSWIRE) -- The Rosen Law Firm, P.A. announces that the United States District Court for the Northern District of California has approved the following announcement of a proposed class action settlement that would benefit purchasers of common stock of Caribou Biosciences, Inc. (NASDAQ: CRBU): SUMMARY NOTICE OF PENDENCY AND PROPOSED SETTLEMENT OF CLASS ACTION TO: ALL PERSONS WHO PURCHASED CARIBOU BIOSCIENCES, INC. ("CARIBOU") COMMON STOCK BETWEEN JULY 23, 2021 AND JULY 13 ...

Caribou Biosciences, Inc. (CRBU) came out with a quarterly loss of $0.38 per share versus the Zacks Consensus Estimate of a loss of $0.44. This compares to loss of $0.12 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 13.64%. A quarter ago, it was expected that this company would post a loss of $0.45 per share when it actually produced a loss of $0.42, delivering a surprise of 6.67%.Over the last four quarters, the company has ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 ______________________________________ FORM 10-Q ______________________________________ (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40631 _______________________ ...

Exhibit 99.1 1 Caribou Biosciences Reports Third Quarter 2024 Financial Results and Provides Business Update -- Advancing four clinical-stage programs for hematologic malignancies and autoimmune diseases; multiple clinical data reports planned for 2025 -- -- Enrolling patients with LBCL (2L and after prior CD19-targeted therapies) with HLA matching strategy in CB-010 ANTLER Phase 1 trial; next data report planned for H1 2025 -- -- Continuing dose escalation portion of the CB-011 CaMMouflage Phase 1 trial in ...

Since my previous article, Caribou Biosciences (NASDAQ: CRBU ) has progressed its gene editing research. It's developing allogeneic therapies against hematological cancers and autoimmune diseases. Currently, CRBU has decided to concentrate on CAR-T therapies and discontinued its CAR-NK platform to optimize resources and extend My name is Myriam Hernandez Alvarez. I received the Electronics and Telecommunication Engineering degree from the Escuela Politecnica Nacional, Quito, Ecuador, the M.Sc. degree in com ...

-- Highly-experienced hematologist and oncologist with proven track record successfully driving global clinical development of CAR-T cell therapies -- BERKELEY, Calif., Aug. 12, 2024 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced the appointment of Tina Albertson, MD, PhD, as chief medical officer. Dr. Albertson brings 15 years of experience leading clinical drug development of cellular therapies and bio ...

Caribou Biosciences, Inc. (CRBU) came out with a quarterly loss of $0.42 per share versus the Zacks Consensus Estimate of a loss of $0.45. This compares to loss of $0.48 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of 6.67%. A quarter ago, it was expected that this company would post a loss of $0.39 per share when it actually produced a loss of $0.46, delivering a surprise of -17.95%. Over the last four quarters, the company ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 ______________________________________ FORM 10-Q ______________________________________ (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40631 ____________________________ ...

Exhibit 99.1 Caribou Biosciences Reports Second Quarter 2024 Financial Results and Provides Business Update -- Advancing four clinical-stage programs for hematologic malignancies and autoimmune diseases; clinical data reports planned for 2024 and H1 2025 -- -- Enrolling 2L LBCL and prior CD19 relapsed LBCL patients based on CB-010 ANTLER Phase 1 data presented at 2024 ASCO Annual Meeting; data to be presented H1 2025 -- -- $311.8 million in cash, cash equivalents, and marketable securities expected to fund ...

Company Overview - Caribou Biosciences, Inc. (CRBU) is expected to report a year-over-year increase in earnings despite lower revenues for the quarter ended June 2024 [1] - The consensus estimate indicates a quarterly loss of $0.45 per share, reflecting a year-over-year change of +6.3% [3] - Revenues are projected to be $3.31 million, down 12% from the same quarter last year [3] Earnings Estimates and Revisions - The consensus EPS estimate has been revised 1.08% higher over the last 30 days, indicating a reassessment by analysts [4] - The Most Accurate Estimate for Caribou Biosciences is lower than the Zacks Consensus Estimate, resulting in an Earnings ESP of -6.67% [10] - The stock currently holds a Zacks Rank of 3, making it challenging to predict an earnings beat conclusively [10] Earnings Surprise History - In the last reported quarter, Caribou Biosciences was expected to post a loss of $0.39 per share but actually reported a loss of $0.46, resulting in a surprise of -17.95% [11] - Over the last four quarters, the company has beaten consensus EPS estimates two times [12] Industry Context - Fortrea Holdings Inc. (FTRE), another player in the Zacks Medical - Biomedical and Genetics industry, is expected to post earnings of $0.07 per share for the quarter ended June 2024, indicating a year-over-year change of -86.5% [16] - Fortrea's revenue is expected to be $686.08 million, down 13.5% from the previous year [16] - The consensus EPS estimate for Fortrea has been revised 2.7% higher over the last 30 days, but it has an Earnings ESP of -17.91% [17]